4.5 Article

Arsenic trioxide attenuates the invasion potential of human liver cancer cells through the demethylation-activated microRNA-491

Journal

TOXICOLOGY LETTERS
Volume 227, Issue 2, Pages 75-83

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.toxlet.2014.03.016

Keywords

Hepatocellular carcinoma; Arsenic trioxide; Matrix metalloproteinases; Epithelial-mesenchymal transition; MicroRNA-491; Nuclear factor kappa B

Categories

Funding

  1. National Natural Science Foundation of China [81171987, 30972507]
  2. Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)

Ask authors/readers for more resources

Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related mortality worldwide. Current standard practices for treatment of HCC are less than satisfactory because of metastasis and recurrence. In addition to treating acute promyelocytic leukemia (APL), arsenic trioxide (As2O3) also suppresses other solid tumors, such as HCC. However, the effects of As2O3 on the migration/invasion potential of liver cancer cells and the molecular mechanisms underlying in remain unclear. Here we found that As2O3 attenuated the migration/invasion potential of HCC cell lines by blocking matrix metalloproteinases (MMPs) activities and inducing a mesenchymal to epithelial transition (MET). Indeed, As2O3 elevated the expression of microRNA-491 (miR-491) via demethylation. On one hand, as a target miRNA of MMP9, miR-491 decreased the MMP9 expression. On the other hand, miR-491 blocked the activation of nuclear factor kappa B (NF-kappa B), which transcriptionally inactivated MMP2 and induced a MET (as determined by the increased expression of E-cadherin and decreased expressions of snail, slug, and vimentin). Knockdown of miR-491 abolished the As2O3-induced MMPs inactivation, MET, and the migration/invasion potential of HCC cell lines. By understanding a novel mechanism how As2O3 inhibits the migration/invasion potential of liver cancer cells, our study may help to identify potential therapeutic targets for liver cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available